Wyeth Pharmaceuticals has launched Premarin*0.3mg (conjugated estrogens), the first low dose estrogen-only HRT, which contains less than half the estrogen i.e. 0.3mg of standard Premarin* 0.625mg (conjugated estrogens).1 This will give healthcare professionals a new option in treating the menopausal symptoms of 1 in 5 women who undergo hysterectomy in the UK before the age of 52.2 Until now, only unhysterectomised women treated with combined progestogen/estrogen HRT, have had a low dose option.
HRT has been shown to be effective in relieving debilitating menopausal symptoms such as hot flushes and night sweats.3 Current guidelines4 recommend that all women going through the menopause who are seeking treatment should be offered a choice of HRT. Treatment with HRT should aim to use the lowest effective dose for the shortest duration and should be reviewed on an annual basis in light of any new knowledge and changes in women's risk factors. Because every woman is different, treatment should be tailored to an individual's need.
"For the hysterectomised woman the availability of new low dose Premarin 0.3mg is a welcome addition. This new low dose option gives practitioners more flexibility in treating these women and allows us to tailor treatment to their individual needs," said Dr John Stevenson, Consultant Physician, Imperial College London.
-- Checking In - Feel Great - Lose Weight The HysterSisters January 'Checking In' eMagazine has been published and should be in your email inbox if you are a regi [More]...